Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
7.75
0.00 (0.00%)
Oct 29, 2025, 4:00 PM EDT - Market open
Nasus Pharma Employees
As of December 31, 2024, Nasus Pharma had 2 total employees, including 1 full-time and 1 part-time employees.
Employees
2
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$766,000
Market Cap
70.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NSRX News
- 22 days ago - Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program - GlobeNewsWire
- 2 months ago - Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony - GlobeNewsWire
- 2 months ago - U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer - Seeking Alpha
- 2 months ago - Nasus Pharma Announces Closing of Initial Public Offering - GlobeNewsWire
- 2 months ago - Nasus Pharma Announces Pricing of $10 Million Initial Public Offering - GlobeNewsWire
- 3 months ago - Nasus Pharma IPO Shows Promise But Risks Remain - Seeking Alpha
- 4 months ago - Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO - Renaissance Capital